RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109

October 14, 2015

RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

"The use of RXI-109 after scar revision surgery has a visible, beneficial effect on suppression of hypertrophic scarring as compared with untreated control scars, at three months following surgery," said Dr. Joseph P. Hunstad, FACS, Founder of The Hunstad Kortesis Center for Cosmetic Plastic Surgery and MedSpa, one of the Principal Investigators in this RXI-109 study.

In the first two arms of this ongoing Phase 2a study, subjects were given six intradermal injections of RXI-109, either at 5mg/cm or 10mg/cm, beginning two weeks after scar revision surgery, with the last of the six doses administered three months post revision surgery. Subjects had one portion of the revised scar treated with RXI-109, whereas another part of the scar was revised but left untreated. This 3-month analysis included 16 subjects of which 15 were evaluable and one was lost to follow-up. Of those 15 subjects, eight were treated with 5mg/cm of RXI-109 and seven were treated with 10mg/cm of RXI-109.  All subjects were assessed using four different evaluation methods:

- POSAS (Physician and Observer Scar Assessment Scale): A compiled score based on investigator assessments of factors contributing to scar quality. These scores are provided by the investigators for both the treated and the untreated portion of the scar of their individual subjects in person;

- VAS (Visual Analogue Scale): A score based on a 10 point scale ranging from "1" (fine line scar) to "10" (worst scar possible) provided by the investigators for their individual subjects;

- A blinded assessment of photographs of the revision sites for 15 subjects by Investigators in which the clinicians were asked to indicate for Scars A and B as to which is 'better' or 'not different';

- A separate assessment of photographs of the revision sites for 15 subjects by a blinded panel, separate from the Investigators, in which the panel members were asked to indicate for Scars A and B as to which is 'better' or 'not different' .

Overall, the RXI-109 treated revision sites were scored statistically significantly better than the untreated revision sites in all four evaluations. Both dose levels of RXI-109 were equally well tolerated with occasional transient redness and itching occurring in both dose levels. The higher dose of 10mg/cm did not appear to add clinical benefit over the 5mg/cm dose, leading to the conclusion that the next cohorts in this ongoing RXI-109-1402 study will be treated with the 5mg/cm dose. These subsequent cohorts will include evaluation of additional treatments through six months to further define the optimum treatment regimen.


Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free